Press Release
Ocular Therapeutix™ Expands Its Board of Directors with the Election of Industry Leader W. James O’Shea
“We are very pleased to announce that Jim is joining our Board. With a
more than 40-year tenure in the biopharma industry, Jim has extensive
commercial expertise, including sales and marketing on an international
scale. We believe his insights will be invaluable as we continue to
advance our lead programs and prepare for launch and commercialization,”
said
For nearly a decade, Mr. O'Shea held leadership positions at
Mr. O'Shea stated, “I am delighted to be joining the Ocular board at a
key time in the Company’s development. With an NDA for DEXTENZA for
post-surgical ocular pain having been recently filed with the
About Ocular Therapeutix, Inc.
Forward Looking Statements
Any statements in this press release about future expectations, plans
and prospects for the Company, including statements about the
development or potential launch and commercialization of the Company’s
product candidates, such as the ongoing development and potential
utility of OTX-DP for post-surgical ocular pain and allergic
conjunctivitis and of OTX-TP for glaucoma, the advancement of the
Company's other product candidates, the potential for the Company’s
sustained release hydrogel depot technology, the Company’s plans for or
success with regulatory submissions, and other statements containing the
words "anticipate," "believe," "estimate," "expect," "intend", "goal,"
"may", "might," "plan," "predict," "project," "target," "potential,"
"will," "would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors. Such forward-looking statements
involve substantial risks and uncertainties that could cause the
Company’s clinical development programs, future results, performance or
achievements to differ significantly from those expressed or implied by
the forward-looking statements. Such risks and uncertainties include,
among others, those related to the timing and costs involved in
commercializing ReSure® Sealant, the initiation and conduct of clinical
trials, availability of data from clinical trials and expectations for
regulatory submissions and approvals, the Company’s scientific approach
and general development progress, the availability or commercial
potential of the Company’s product candidates, the sufficiency of cash
resources and need for additional financing or other actions and other
factors discussed in the “Risk Factors” section contained in the
Company’s quarterly and annual reports on file with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20151109006375/en/
Source:
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich,
212-213-0006
kminarovich@burnsmc.com
or
Justin
Jackson
jjackson@burnsmc.com
or
Media
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Sales and
Marketing
scorning@ocutx.com